Related Experiment Video
Updated: Jul 6, 2026
08:17
Flow Cytometry-based Assay for the Monitoring of NK Cell Functions
Published on: October 30, 2016
[New drugs; natalizumab]
H van Bronswijk1, E A Dubois, J M A van Gerven
1Leids Universitair Medisch Centrum, Albinusdreef 2, 2333 ZA Leiden.
Nederlands Tijdschrift Voor Geneeskunde
|April 9, 2008
Summary
Natalizumab is a new treatment for multiple sclerosis (MS) that reduces relapses. While effective, severe side effects like progressive multifocal leukoencephalopathy warrant further investigation.
Area of Science:
- Immunology
- Neurology
- Pharmacology
Context:
- Multiple sclerosis (MS) is a chronic autoimmune disease affecting the central nervous system.
- Natalizumab offers a novel therapeutic strategy for highly active relapsing-remitting MS.
- Understanding the mechanism of action and safety profile is crucial.
Purpose:
- To evaluate natalizumab as a treatment for very active relapsing-remitting multiple sclerosis.
- To assess the efficacy of natalizumab in reducing disease activity and progression.
- To identify and characterize adverse events associated with natalizumab therapy.
Summary:
- Natalizumab, a humanized monoclonal antibody, targets lymphocyte trafficking by inhibiting integrin binding.
- It prevents lymphocyte transmigration across the endothelium, thereby reducing neuroinflammation in MS.
- Clinical studies demonstrate a decrease in relapse rates and disease progression.
Impact:
- Natalizumab represents a significant advancement in MS pharmacotherapy.
- Severe adverse events, including progressive multifocal leukoencephalopathy (PML), necessitate careful patient monitoring.
- Ongoing research is essential to fully elucidate the long-term clinical utility and safety of natalizumab.
More Related Videos
Related Concept Videos
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates these...
01:26FDA Approved Drugs: Changes to Approved Drugs
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:27Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:14Antiepileptic Drugs: Glutamate Antagonists
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...